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Background: Telaprevir (TVR) has been approved for response-guided-therapy (RGT) of chronic hepatitis C (HCV)
genotype-1-infection in treatment-naïve and –experienced patients. In RGT-regimens patients that did not achieve
extended rapid-virological-response (eRVR) within the first 4–12 weeks undergo treatment for 48-weeks, whereas in
fixed-length-treatment (FLT) patients are treated for a fixed-duration regardless of their RVR.
Methods: This systematic review and Bayesian mixed-treatment-comparison (MTC) aimed to compare the efficacy
and safety of standard-therapy with pegylated-interferon-α/ribavirin (Peg-IFN-α/RBV (48 weeks), group A), FLT with
TVR, Peg-IFN-α/RBV for 12 weeks with a long (+36 weeks, group B) or short (+12 weeks, group C) tail of Peg-IFN-α/
RBV treatment, and RGT with 12 weeks of TVR, Peg-IFN-α/RBV followed by 12 weeks of Peg-IFN-α/RBV (group D) or
no therapy (group E).
Results: We identified seven randomized controlled trials including 3505 patients. Compared to standard-treatment
(group A), treatment-naïve patients allocated to groups B, C, and D were significantly more likely to achieve
sustained-virological-response (SVR, odds ratios (OR): B vs. A 3.5 (credibility interval [CrI] 2.2-5.4), C vs. A 3.0
(CrI 1.8-4.9), D vs. A 3.4 (CrI 2.5-4.6)). Treatment-experienced patients achieved increased SVR rates when they were
treated in group B (OR: 8.2 (CrI 5.0-13.5)), C (OR 7.0 (CrI 3.9-12.8)), or simulated group D (OR 8.2 (CrI 4.3-15.3)).
Patients treated with short RGT (simulated group E) did also have a significant improvement when they were
treatment-experienced (simulated OR 3.6 (CrI 1.6-8.2)), whereas the effect was not significant in treatment-naïve
patients (OR E vs. A 1.6 (CrI 0.9-2.7)).
Conclusion: Long FLT and RGT regimens are useful treatment options for HCV-genotype-1 in both treatment-naïve
and -experienced patients. A short 24-weeks FLT regimen does not seem to be inferior and should further be
evaluated in clinical trials to reduce side effects and costs of treatment.
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Approximately 170 million people worldwide are infec-
ted chronically with the hepatitis C virus (HCV) [1].
Since 2001, the combination of pegylated interferon-α
(Peg-IFN-α) plus ribavirin (RBV) has been the standard-
of-care treatment for patients with HCV infection [2-4].
New direct-acting antiviral agents such as HCV NS3/4A
protease inhibitors are one of the most promising drug
targets for HCV [5]. NS3/4A HCV protease inhibitors
achieve high antiviral potency by blocking HCV poly-
protein cleavage and may also neutralize HCV NS3
protease-mediated interference with the innate immune
system. Through this mechanism, HCV NS3/4A prote-
ase inhibitors reverse the HCV NS3 protein’s capacity to
block intracellular signal-transduction pathways for
endogenous IFN production in vitro and may also do so
in vivo [6,7]. The recent approval of two novel HCV
nonstructural protein NS3/4A protease inhibitors
(telaprevir and boceprevir) heralds a new era in the
treatment of chronic hepatitis C [8-13]. Clinical trials
demonstrate that telaprevir (TVR) in combination with
Peg-IFN-α and RBV improve treatment efficacy in both
treatment-naïve [10,14-16] and -experienced patients
[11,13] when compared to the standard treatment of
Peg-IFN-α and RBV. These large randomized trials
examined different treatment regimens: Fixed-length
treatment (FLT) versus response-guided treatment
(RGT) duration as a triple therapy including TVR with a
varying Peg-IFN-α and RBV treatment tail. TVR has to
be administered three times per day with a fatty meal.
Treatment with TVR is more expensive and also has
additional side effects including rash, pruritus, anemia,
dysgeusia and gastrointestinal symptoms. The rate of
treatment discontinuation in patients treated with a
TVR-based therapy was between 10-18% [11,13,17]. The
Food and Drug administration (FDA) approved TVR as
RGT for treatment-naïve and prior Peg-IFN-α and RBV
relapsers without prospective evaluations in randomized
controlled trials [18]. Because of the higher rate of
adverse effects and costs associated with these various
therapeutic options referring to the use of TVR, it is
important to determine the relative efficacy and safety of
these FLT and RGT options using TVR as compared to
that of the standard treatment consisting of Peg-IFN-α
and RBV only.Methods
The inclusion and exclusion criteria, outcome mea-
sures, methods of literature search, selection, data
extraction and statistical analysis were defined in a
protocol according to the recommendations in the
Cochrane Handbook for Systematic Reviews of Inter-
ventions [19].Endpoints and definitions
The primary endpoint was the proportion of patients
who achieved sustained virological response (SVR)
defined as undetectable plasma HCV RNA 24 weeks
after the last planned dose of the study treatment. The
secondary end points were safety, as assessed by the
percentage of patients who discontinued therapy due to
adverse events (AE) and the incidence of serious adverse
events (SAE) as defined by the International Conference
on Harmonisation, Guidelines for Good Clinical Practice
(ICH GCP) [20].
Undetectable HCV-RNA at week 4 of treatment was
defined as rapid virological response (RVR). When RVR
was persistent in the following weeks it was defined as
extended RVR (eRVR). Relapse occurs when HCV RNA
decreases and remains below the limit of detection
during treatment but becomes detectable after cessation
of treatment. Null-response was defined as less than < 2
log10 reduction in serum HCV RNA from baseline dur-
ing treatment. Partial response was defined as ≥ 2 log10
reduction from baseline HCV RNA at week 12, but with
virus remaining detectable through week 24 or end of
treatment.
Inclusion and exclusion criteria
For inclusion into this analysis, studies had to fulfill the
following criteria. They had to be: (1) randomized, pro-
spective trials; (2) compare the efficacy of TVR with
conventional doses of Peg-IFN-α-2a (180 μg/week) or
Peg-IFN-α-2b (1.5 μg/kg of body weight/week), both in
combination with RBV; (3) report the primary outcomes,
i.e., SVR, as defined above; and had to be performed (4)
in patients with a chronic HCV genotype 1 infection.
Additionally, included trials had to report results on at
least two of the following five treatment groups (Figure 1):
(A) standard treatment with Peg-IFN-α and RBV for
48 weeks; (B) FLT with either 12 weeks of TVR in com-
bination with Peg-IFN-α and RBV followed by 36 weeks
of treatment with Peg-IFN-α and RBV or 24 weeks of
treatment with TVR, Peg-IFN-α, and RBV followed by
24 weeks of Peg-IFN-α and RBV (overall treatment dur-
ation 48 weeks); (C) 12 weeks of TVR in combination with
Peg-IFN-α and RBV followed by 12 weeks of treatment
with Peg-IFN-α and RBV (overall treatment duration
24 weeks); (D) RGT with 12 weeks of TVR, Peg-IFN-α
and RBV followed by 12 weeks of treatment with Peg-
IFN-α and RBV for patients that had eRVR and 36 weeks
of treatment for patients that had no eRVR; (E) RGT with
12 weeks of TVR, Peg-IFN-α and RBV followed by no
further treatment for patients that had eRVR or 36 weeks
of treatment with Peg-IFN-α and RBV for patients that
had no eRVR. Treatment arms in which patients received
no RBV or a treatment duration with TVR that was less
than 12 weeks duration were excluded.
Figure 1 Treatment regimens; TVR: telaprevir; IFN: pegylated interferon-α; RBV: ribavirin.
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lished an analysis of Peg-INF-α, RBV and TVR regimens
who demonstrated that interferon responsiveness does
not change in Peg-IFN-α/RBV-experienced subjects with
a second round of Peg-IFN-α/RBV [18,21]. Based on this
assumption we included both studies with treatment-na
ïve and -experienced patients, i.e. patients that already
had treatment with Peg-IFN-α/RBV but had relapse,
null or partial response. To account for differences in
baseline responsiveness and magnitude of the effect
of TVR we stratified the statistical analysis to account
for treatment status, i.e., treatment-experienced versus
treatment-naïve.
Literature search, selection, and data extraction
A systematic literature search was performed without
language restrictions from inception to 25 February
2013 in the following databases: Medline/PubMed and
Web of Science. The keywords used were “telaprevir” or
“VX-950”. General reviews, meta-analyses, and refer-
ences from published randomized controlled trials
(RCTs) and presentation to the International Association
for the Study of the Liver, the European Association for
the Study of the Liver and the American Association for
the Study of Liver Diseases Meetings were also searched
for additional citations. Publications were reviewed
independently by two reviewers (A.A. and A.D.G) in a
two-stage process. Disagreement and any discrepancies
were resolved by discussion. Data extraction was perfor-
med by both reviewers, using a standardized form.
Risk of bias
The risk of bias was assessed independently by both
reviewers (A.A. and A.D.G.) without blinding to journal
and authorship. The quality items assessed were sequen-
ce generation, allocation concealment, blinding of par-
ticipants and outcome, completeness of follow-up, and
whether problems with incomplete outcome data were
appropriately addressed. We also assessed selective
reporting and a defined low risk of bias when a detailedstudy registration was available and the complete study
protocol had been published. Assessments were perfor-
med according to the definitions stated in the Cochrane
Handbook [19]. We included data on all randomized
patients, regardless of treatment completion. Data concer-
ning only those patients who completed the assigned
treatment (“per protocol”) was not available for most
included studies and could therefore not be evaluated.
Data analysis
Bayesian mixed treatment comparison (MTC) meta-
analysis is increasingly used when there are multiple
possible treatment options that have not been compared
directly but each has been compared to a standard treat-
ment, or when two or more new drugs have been tested
against a common standard but no direct evidence on a
head-to-head comparison is available. The framework of
Bayesian MTC meta-analysis as described by Lu et al.
[22] combining direct and indirect evidence on any com-
parison of the defined treatment groups was utilized.
This method of MTC allows an indirect comparison of
treatments A and B, although only data on studies
comparing one of the two treatments against a third
comparator C can be analyzed. For example, TVR and
boceprevir were compared in a MTC meta-analysis [23],
and the indirect evidence suggests that TVR may be
more efficacious for prior relapse but not for treatment
naïve patients.
The model utilized included random effect baselines
as well as homogenous treatment variance. The model
was extended to account for different study populations,
i.e., treatment-naïve and -experienced patients, by strati-
fication. In general, we used vague priors and calculated
median and 95% credibility intervals (CrI), which are the
Bayesian equivalent of confidence intervals from the
posterior distribution. Analyses were performed with R
version 2.15.2 [24] in combination with JAGS [25].
Additionally, we used the R packages R2jags, ggplot2,
and ggmcmc to analyze and visualize results of the
Markov Chain Monte Carlo (MCMC) simulation.
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reached as indicated by the visual analysis of the
traceplots, the running mean and the density of the pos-
terior distribution of the separate chains (all provided as
supplemental material). The Gelman and Rubin statistic
for all parameters presented was below 1.05. Because of
autocorrelation for some parameters, we applied thin-
ning of the chains and reached acceptable effective
sample sizes for all analyzed parameters.
Results
A total of 1018 publications were identified through
electronic database and manual search using the above
reported keywords (Figure 2), of which 252 were exclu-
ded as duplicates. Of the 766 publications that qualified
for abstract review, 695 were excluded primarily because
they were not randomized or TVR was not compared in
the study. 71 were considered potentially relevant but
only 7 [10,11,13-17] met the inclusion criteria and were
included in the meta-analysis.
Table 1 shows the characteristics of the included stud-
ies and allocation of their treatment arms to the defined
treatment groups of this review. Seven published phase
II and III randomized placebo-controlled trials provided
efficacy and safety data among 3505 patients treated
with TVR in combination with Peg-IFN-α plus RBV. Five
of these trials were conducted in 2390 treatment-naïve
patients [10,15-17] and two were conducted in 1115
treatment-experienced patients [11,13]. The populations
were comparable in terms of age and gender. In
terms of genosubtype, the study of Kumada et al. [15]Figure 2 Flow chart of systematic review of telaprevir.and Hezode et al. [16] represented an exception since a
population was included that predominantly contained
genosubtype 1b; genosubtype 1a was the most common
genotype among the populations recruited in all other
trials. Of note, none of these trials allowed the use of
erythropoietin therapy to treat anemia.
The overall treatment duration varied between 12 to
48 weeks with a TVR treatment duration of 12 weeks.
Two treatment arms included different TVR-treatment
durations, one with 8 weeks [10] and the other with
24 weeks [11] (Table 1) as well as two arms without the
use of RBV [11,14]. Those were excluded from the
analysis. Two trials [10,16] were designed to report on
what seemed to be FLT, however patients in the TVR-
treatment arms that did not have eRVR were considered
non-responders and were continued on Peg-IFN-α/RBV
for an overall treatment length of 48 weeks. These trials
could not be included in the analysis as FLT regimens as
it was unclear, how many patients without eRVR would
eventually reach SVR without extending the treatment.
In both trials, the authors report SVR data after exten-
sion of the treatment to the full 48 weeks course. These
data were included in our analysis as RGT regimens. In
the trial of Sherman et al. [17], all patients received
12 weeks of triple therapy. Patients without eRVR con-
tinued on Peg-IFN-α/RBV for a full course of 48 weeks
whereas patients with eRVR were randomized to receive
only 12 or 36 weeks of treatment with Peg-IFN-α/RBV.
From these three cohorts we simulated two cohorts with
a 48 weeks FLT regimen and a 24+24 weeks RGT
treatment.
TVR was given as a single dose of 1250 or 1125 mg on
study day 1, followed by a dose of 750 mg every 8 hours
orally in the 3 phase 2 trials [11,16]. It was administered
orally at a dose of 750 mg every 8 hours with food in the
4 phase 3 trials [10,13,15,17]. All the included trials
utilized Peg-IFN-α2a at 180 μg/week and a weight
adjusted RBV dose between 1000 to 1200 mg/day except
the trial published by Kumada et al. [15] who used Peg-
IFN-α2b at 1.5 μg/kg/week and a weight adjusted RBV
dose between 600 to 1000 mg/d (Table 1).
All trials were randomized and all but the ILLUMIN-
ATE trial published by Sherman and colleagues were
double blind. Six studies [10,11,13,16,17] were funded by
pharmaceutical companies. The methods of trial conduct
and statistical analysis were adequate and documented
in detail in the original publication or the study protocol,
which was published as supplemental material. Only
insufficient information concerning the risk of bias was
available for the study published by Kumada and
colleagues [15].
Three studies measured the plasma HCV-RNA level
with the use of the COBAS TaqMan HCV assay, version
1.0 (Roche Molecular Systems), with a lower limit of























[16] McHutchison et al. 2009 Naïve RGT 12 E 17 49 12 (71) 6 (35) 12 α2a: 180 μg 1000-1200
RGT 24 D 79 49 54 (68) 17 (22) 12 α2a: 180 μg 1000-1200
FLT 48 B 79 50 48 (61) 27 (34) 12 α2a: 180 μg 1000-1200
Control 48 A 75 49 43 (57) 20 (27) none α2a: 180 μg 1000-1200
[14] Hezode et al. 2009 Naïve RGT 12 E 82 44 49 (60) 45 (55) 12 α2a: 180 μg 1000-1200
RGT 24 D 81 46 54 (67) 50 (62) 12 α2a: 180 μg 1000-1200
RGT 12 NI 78 45 43 (55) 38 (49) 12 α2a: 180 μg none
Control 48 A 82 45 46 (56) 45 (55) none α2a: 180 μg 1000-1200
[11] McHutchison et al. 2010 Experienced FLT 24 C 115 51 78 (68) 33 (29) 12 α2a: 180 μg 1000-1200
FLT 48 B 113 52 80 (71) 42 (37) 24 α2a: 180 μg 1000-1200
FLT 24 NI 111 53 72 (65) 36 (32) 24 α2a: 180 μg none
Control 48 A 114 50 76 (67) 34 (30) none α2a: 180 μg 1000-1200
[10] Jacobson et al. 2011 Naïve RGT 24 (+24) D 363 49 214 (59) 149 (41) 12 α2a: 180 μg 1000-1200
RGT 24 (+24) NI 364 49 211 (58) 151 (41) 8 α2a: 180 μg 1000-1200
Control 48 A 361 49 211 (58) 151 (42) none α2a: 180 μg 1000-1200
[13] Zeuzem et al. Experienced FLT 48 B 266 51 183 (69) 121 (45) 12 α2a: 180 μg 1000-1200
FLT 48 NI 264 51 189 (72) 115 (44) 16 α2a: 180 μg 1000-1200
Control 48 A 132 50 88 (67) 59 (45) none α2a: 180 μg 1000-1200
[17] Sherman et al. 2011 Naïve RGT 24 (+24) D 221 NA NA NA 12 α2a: 180 μg 1000-1200
FLT 48 B 219 NA NA NA 12 α2a: 180 μg 1000-1200
[15] Kumada et al. 2012 Naïve FLT 24 C 126 53 66 (52) 124 (98) 12 α2b: 1.5 μg/kg 600-1000
Control 48 A 63 55 33 (52) 63 (100) none α2b: 1.5 μg/kg 600-1000
No: number; TVR: telaprevir; mg: milligram; d: day; RBV: ribavirin; RGT: response-guided treatment; FLT: fixed-length treatment; control: standard treatment; NI: not included; NA: not available; *pseudo-groups merged
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detection of 10 IU per milliliter [11,14,16]. Four studies
measured the plasma HCV-RNA level with the use of
the COBAS TaqMan assay (Roche Molecular Systems,
version 2.0), which has a lower limit of quantification of
25 IU per milliliter and a lower limit of detection of
approximately 10 to 15 IU per milliliter [10,13,15,17].
The structure of the MTC network is shown in
Figure 3 with the naming scheme of the nodes cor-
responding to the treatment regimens as shown in
Figure 1. Several trials compared more than two treat-
ment arms [10,11,13,16].
It must be noted that only two studies [11,13] were
performed with treatment-experienced patients, which
only provided data for regimen groups A, B and C.
Hence, treatment-experienced patients have only been
studied in FLT regimens although the FDA has approved
RGT treatment for prior relapsers [18].
Efficacy in treatment-naïve patients
The primary efficacy endpoint (Figure 4) SVR, was
reached significantly more often in the two FLT TVR
regimens (75% [CrI 53 to 87%] in group B, 72% [CrI 50
to 87%] in group C) and in the long RGT triple regimen
(group D: 75% [CrI 53 to 88%]) compared to standard
treatment (group A: 46% [CrI 27 to 67%]). There was no
significant difference for the short RGT TVR regimen
(group E: 57% [CrI 32 to 78%]) compared to the stand-
ard treatment. Comparison of the TVR regimens shows
that there was no significant difference between the two
FLT regimens and the long RGT treatment. All threeFigure 3 Structure of mixed treatment comparison network.
Node labels: A, standard treatment (Peg-IFN-α/RBV 48 weeks);
B, fixed-length treatment (FLT) with long tail (TVR 12 weeks/Peg-IFN-
α/RBV 48 weeks); C, FLT with short tail (TVR 12 weeks/ Peg-IFN-α
/RBV 24 weeks); D, response-guided treatment (RGT) with tail (TVR
12 weeks/ Peg-IFN-α/RBV 24 weeks/or Peg-IFN-α/RBV 24 weeks);
E, RGT without tail (TVR 12 weeks/ Peg-IFN-α/RBV 12 or 36 weeks).
Edges indicate comparisons in trials denoted by number
(see Table 1); black numbers: treatment-naïve patients; red numbers:
treatment experienced patients.were found to be superior to the short RGT regimen.
This result implies that the long RGT regimen is not
inferior to a 48 weeks FLT regimen (OR of group D vs. B:
1 [CrI 0.6 to 1.5]). Furthermore, the long RGT regimen
and the 48 weeks FLT regimen were not superior to the
24 weeks FLT (OR of group B vs. C 1.2 [CrI 0.8 to 1.9]
and D vs. C 1.2 [CrI 0.7 to 1.9]).
Efficacy in treatment-experienced patients
Only two pivotal studies were performed for treatment-
experienced patients. They provided data only for
regimens of group A, B and C. Group D and E were
simulated in this bayesian MTC from direct and indirect
evidence obtained in treatment-naïve and -experienced
patients. As expected, overall treatment efficacy was
lower in treatment- experienced patients (Figure 5). The
rate of SVR was significantly higher in each of the four
TVR regimens – 59% (CrI 36 to 81%) in group B, 55%
(CrI 31 to 79%) in group C, 59% (CrI 34 to 82%) in the
simulated group D, and 39% (CrI 17 to 70) in the simu-
lated group E – compared to standard treatment (group
A: 15% [CrI 6 to 34%]). The results of patients treated
with the short FLT regimen were comparable to the
results for the long FLT and simulated long RGT regimen.
In contrast, the simulated short RGT regimen was inferior
as compared to the simulated long RGT regimen.
Safety of triple therapy
The expected incidences of SAE and AE leading to treat-
ment discontinuation are shown in Figures 6 and 7.
Both, SAE and AE leading to treatment discontinuation
were observed significantly more often in treatment
group B compared to the control group (OR 3.8 [CrI 1.1
to 7.5] and 2.3 [CrI 1.3 to 3.9], respectively), whereas
there was only a small albeit non-significant increase in
SAE/AE in the other treatment groups. SAE/AE in the
RGT groups D and E and in the short FLT group C were
lower than in the long-tail treatment group B, e.g., for
group D vs. B the OR for SAE was 0.5 (CrI 0.3 to 0.9)
and the OR for AE leading to discontinuation was 0.3
(CrI 0.2 to 0.9). Between treatment groups C through E
there was no significant difference in the incidence of
SAE and AE leading to treatment discontinuation.
Discussion
This study compared the efficacy and safety of different
TVR-based triple therapy regimens in treatment-naïve
and -experienced chronic HCV genotype 1 infected
patients. Although these different treatment regimens
still have not been yet compared in a randomized trial
but triple therapy with TVR has been approved for
treatment of HCV genotype 1 infections. Utilizing both
direct and indirect evidence, various treatment groups
and a network of comparisons (Figure 3) were used for a
Figure 4 Results of bayesian mixed treatment comparison for treatment-naïve patients. The upper node part indicates the treatment
group [Node labels: A, standard treatment (Peg-IFN-α/RBV 48 weeks); B, fixed-length treatment (FLT) with long tail (TVR 12/24 weeks/Peg-IFN-α/
RBV 48 weeks); C, FLT with short tail (TVR 12 weeks/Peg-IFN-α/RBV 24 weeks); D, response-guided treatment (RGT) with tail (TVR 12 weeks/Peg-
IFN-α/RBV 24 and/or 24 weeks); E, RGT tail (TVR 12 weeks/Peg-IFN-α/RBV 12 or 36 weeks), the lower node part gives the median proportion of
patients (in percent) with sustained virological response (SVR, credible 95% bayesian intervals in square brackets). The edges indicate comparisons
with the arrowhead indicating the comparator (i.e. baseline). The odds ratio of the respective comparison is shown with credible 95-% intervals of
the bayesian analysis in square brackets. Dashed lines (and red text color) indicate comparison that was not observed but only simulated.
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based regimens compared not only to a common com-
parator, i.e., standard therapy, but also to each other.
The main results of this analysis are that (i) the addition
of TVR increases the likelihood of achieving SVR inFigure 5 Results of bayesian mixed treatment comparison for treatm
treatment group [Node labels: A, standard treatment (Peg-IFN-α/RBV 48 we
Peg-IFN-α/RBV 48 weeks); C, FLT with short tail (TVR 12 weeks/Peg-IFN-α/RB
(TVR 12 weeks/Peg-IFN-α/RBV 24 and/or 24 weeks); E, RGT without tail (TVR
the median proportion of patients (in percent) with sustained virological re
Nodes with red background have not been observed and have only been
with the arrowhead indicating the comparator (i.e. baseline). The odds ratio
the bayesian analysis in square brackets. Dashed lines (and red text color) itreatment-naïve and -experienced chronic HCV genotype
1 patients, (ii) the long FLT and RGT regimen (groups B
and D) are equally effective, (iii) the short RGT regimen
(group E) is only marginally more effective compared to
standard therapy and it is inferior compared to the otherent experienced patients. The upper node part indicates the
eks); B, fixed-length treatment (FLT) with long tail (TVR 12/24 weeks/
V 24 weeks); D, response-guided treatment (RGT) with tail
12 weeks/Peg-IFN-α/RBV 12 or 36 weeks), the lower node part gives
sponse (SVR, credible 95% bayesian intervals in square brackets).
simulated from the bayesian model. The edges indicate comparisons
of the respective comparison is shown with credible 95-% intervals of
ndicate comparison that was not observed but only simulated.
Figure 6 Serious adverse events of mixed treatment comparison network. Node labels: A, standard treatment (Peg-IFN-α/RBV 48 weeks);
B, fixed-length treatment (FLT) with long tail (TVR 12/24 weeks/Peg-IFN-α/RBV 48 weeks); C, FLT with short tail (TVR 12 weeks/Peg-IFN-α/RBV
24 weeks); D, response-guided treatment (RGT) with tail (TVR 12 weeks/Peg-IFN-α/RBV 24 and/or 24 weeks); E, RGT without tail (TVR 12 weeks/
Peg-IFN-α/RBV 12 or 36 weeks). The edges indicate comparisons with the arrowhead indicating the comparator (i.e. baseline). The odds ratio of
the respective comparison is shown with credible 95-% intervals of the bayesian analysis in square brackets. Dashed lines (and red text color)
indicate comparison that was not observed but only simulated.
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inferior to the long FLT and RGT regimens. Off note
is that the results of group D and E for treatment-
experienced patients presented in this study was simulated
and has not been applied in prospective randomized
studies yet.
Several large multi-center trials have been performed
to assess the efficacy and safety of TVR in patients with
chronic HCV genotype 1 infection. The results show
that in most patients and under most circumstances,Figure 7 Serious adverse events leading to treatment discontinuation
treatment (FLT) with long tail (TVR 12/24 weeks/Peg-IFN-α/RBV 48 weeks); C
D, response-guided treatment (RGT) with tail (TVR 12 weeks/Peg-IFN-α/RBV
12 or 36 weeks).TVR increases the likelihood of achieving a SVR. Different
TVR treatment strategies were employed to document the
superiority of TVR but also to explore differing treatment
durations. As expected, not all regimens were equally
effective. Hofmann et al. [26] conclude that RGT with
12 weeks of TVR, Peg-IFN-α and RBV, followed by
12 weeks of Peg-IFN-α and RBV for all patients and an
additional 24 weeks of Peg-IFN-α and RBV for patients
who did not achieve RVR appears to be the best treatment
regimen, although no direct comparison to other treatment. A, standard treatment (Peg-IFN-α/RBV 48 weeks); B, fixed-length
, FLT with short tail (TVR 12 weeks/Peg-IFN-α/RBV 24 weeks);
24 and/or 24 weeks); E, RGT without tail (TVR 12 weeks/Peg-IFN-α/RBV
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been assessed in treatment experienced patients.
In our analysis, TVR-based treatment regimen de-
monstrated a boost in achieving SVR in both treatment-
naïve and –experienced patients, with the OR value
in treatment-naïve patients lower than in treatment-
experienced patients. Moreover, the FLT regimen showed
better overall SVR rates and OR results in treatment-naïve
patients compared to the RGT regimen. Patients with a
FLT duration of 12 weeks triple therapy followed by
12 weeks of Peg-IFN-α and RBV in total showed a SVR
rate of 72% despite a shorter treatment duration. The
length of treatment duration in RGT in TVR protocols is
being discussed. In one open-label study designed to in-
vestigate the effects of RGT, patients with eRVR to triple
therapy were randomized to 24 or 48 weeks of standard
treatment to evaluate whether 48-week therapy can gain
further benefits [17]. The results showed no further bene-
fit from the 12-week triple therapy over the 48-week
standard therapy in patients with eRVR. Collectively, the
TVR 12 and Peg-IFN-α/RBV 24 weeks protocol resulted
to be more effective and could shorten the therapy dur-
ation compared with standard treatment, thus possibly
serving as the treatment of choice for chronic HCV geno-
type 1 infection. Interestingly, the patients of group E did
not achieve significantly higher SVR rates compared to a
standard treatment for 48 weeks. Although SVR rates may
not be statistically different, it should be acknowledged
that the 12 weeks triple regimen is much shorter than the
48 weeks standard treatment and may therefore offer
reduction of side effects at equal efficacy. Our data suggest
that the chance of treatment failure is likely to be similar
despite a longer treatment duration, and that FLT regimen
would be a good option if the virus is cleared early. It may
be possible to prospectively study this hypothesis in prior
partial and null responders; however, the study size and
enrollment time for such a trial is likely to be impractical
given the rapid pace of HCV drug development. This issue
is now a point of interest as the FDA approved a RGT
scheme for treatment-naïve and –experienced patients
[18]. At the time when the FDA approved this regimen,
only three phase 3 studies had evaluated the RGT regimen
[10,13,17]. The RGT regimen was prospectively evaluated
only in two registration trials of treatment-naïve subjects
[10,17]. In these studies, the RGT regimen allowed
subjects who achieved eRVR, to stop all treatments at
week 24. The RGT regimen was not prospectively evalu-
ated in prior relapsers. Therefore, the FDA used data from
cross-study comparison which indicated that SVR rates
were 62-77% in prior partial responders and 62-71% in
prior null responders who achieved eRVR, irrespective of
standard treatment duration (24 or 48 weeks), suggesting
that the RGT regimen might also be suitable in prior
partial and null responders [18]. Our simulated data fortreatment-experienced patients shows that a RGT regimen
for 12 weeks triple therapy followed by either 12 or
24 weeks of standard treatment could achieve a SVR of
59% with an OR of 8.2 compared to the control group.
Safety is the biggest concern when TVR-based therapy
regimens are used. Despite theencouraging efficacy in
terms of enhanced SVR and decreased relapse rates,
TVR combination treatment is coupled with an increa-
sed incidence of adverse events, including but not
limited to rash, anemia, pruritus, anemia, fatigue, flu-like
syndrome, headache, nausea, insomnia, diarrhea, and
pyrexia, among which rash and anemia are the most
common adverse events. These adverse events can lead
to discontinuation of treatment in severe cases. The inci-
dences of both SAE and discontinuation of treatment
are increased with TVR-based regimen, as shown in this
Bayesian MTC. Therefore, the use of TVR is limited in
interferon-intolerant patients, and caution should be
taken when TVR is used over a long period of time.
Since the currently used standard therapy already has
numerous adverse effects, we tried to discover whether
the potentially shortened treatment duration by adding
TVR can reduce the drug toxicity of a longer treatment
period with Peg-IFN-α and RBV. Interestingly, this
Bayesian MTC demonstrated that the group of patients
that initially received 12 weeks triple therapy followed
by a fixed-length 24-weeks-treatment with Peg-IFN-α
and RBV had the lowest rate of adverse events and
discontinuation rate.
Strength and weaknesses
In this analysis the results from treatment-naïve or –
experienced patients were pooled and analyzed. Five of
the included trials investigated the efficacy and safety of
TVR in treatment-naïve patients, where only two studies
examined treatment-experienced patients. This is a major
limitation of this Bayesian MTC. Recently, empirical
cross-trial data on triple therapy presented and analyzed
by the FDA [18] implied that in prior relapsers, interferon
responsiveness does not change in Peg-IFN-α/RBV-
experienced subjects. The rationale to pool different patient
populations was based on this report. Because the differ-
ence in previous treatment status may increase heterogen-
eity and become a potential liability, in this Bayesian MTC
a stratified analysis was performed. The stratified MTC
analysis allows, for the first time, an estimate of the effect
of RGT in treatment-experienced patients to be deter-
mined. Nevertheless, it must be noted that the results of
treatment-experienced patients with RGT regimen are
only simulated.
Another considerable difference in the patient popula-
tion was the definition of in- or exclusion criteria for
patients with cirrhosis, as it is known to be associated
with a reduced SVR [2,4]. In two trials patients with
Goralczyk et al. BMC Gastroenterology 2013, 13:148 Page 10 of 11
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patients with decompensated cirrhosis were excluded. A
stratified analysis was not possible due to the small
number of trials that excluded patients with cirrhosis.
Differences in efficacy of TVR in cirrhosis were therefore
not analyzed.
There are seven randomized trials included in this
Bayesian MTC. Six studies were supported by phar-
maceutical industry, which may weaken the strength of
evidence demonstrated in this article, although the num-
ber of patients included in these 7 randomized trails was
fairly large. The heterogeneity of the study collective for
this analysis is relatively high, due to the small number
of included randomized trails and the different study
populations and treatment durations. Inter-study vari-
ation may compromise the reliability of these results.
However, sensitivity analysis showed that the results of
our analysis were stable and reliable. Finally, most of
the populations studied here are caucasians, thus the
conclusion may not be true for other races or areas. All
these limitations point out the direction for future
studies.
The therapy options for individuals with chronic HCV
genotype 1 infection are widening. To offer these patients
the best possible therapy, various predictive factors need
to be be assessed before initiating therapy. These factors
include demographics, virology, host allelic variation of
interleukin-28B and interferon-λ4, laboratory values and
histological features [26-29]. A treatment-naïve patient
with favorable predictive factors probably does not
need a triple therapy but can be effectively treated
with a standard antiviral therapy consisting of Peg-
IFN-α and RBV.
Conclusion
This study confirms results that have already been found
in other meta-analyses, i.e., that the addition of TVR in-
creases the likelihood of achieving a SVR in both
treatment-naïve and -experienced patients. In addition,
the present report suggests that the SVR achieved in
treatment-experienced patients with long TVR-RGT is
comparable with 48 weeks TVR-FLT with a lower risk of
SAE and concurs with the rationale presented by the
FDA that led to the approval of RGT in treatment-
experienced patients.
Furthermore, a short, 24 week TVR-FLT regimen was
not found to be inferior to a longer treatment regimen
which implies that the additional 24 weeks of treatment
with Peg-IFN-α and RBV does not increase the chance
of achieving SVR in patients without an eRVR. It may
therefore be viable to compare a shorter 24-weeks FLT
regimen to a RGT treatment regimen to reduce the cost
and consequences of possibly futile additional Peg-IFN-
α/RBV treatment in patients without eRVR.Competing interests
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